Status:
COMPLETED
Use of Topotecan in Patients With Refractory Acute Leukemia
Lead Sponsor:
US Department of Veterans Affairs
Collaborating Sponsors:
Immunex Corporation
SmithKline Beecham
Conditions:
Non-Hodgkin's Lymphoma
Leukemia
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to identify the highest tolerated doses in drugs used to treat aggressive leukemia, lymphoma or multiple myeloma not responding to standard chemotherapy treatment. The dru...
Detailed Description
The purpose of this study is to identify the highest tolerated doses in drugs used to treat aggressive leukemia, lymphoma or multiple myeloma not responding to standard chemotherapy treatment. The dru...
Eligibility Criteria
Inclusion
- Patients in the following disease categories will be considered eligible for this study:
- Any acute leukemia beyond an initial attempt to induce a remission or after relapse
- Chronic Myelogenous Leukemia in Blast Phase
- Refractory Multiple Myeloma
- Refractory non-Hodgkin's and Hodgkin's Lymphoma
- Patients must be more than 14 days beyond prior myelotoxic chemotherapy
- Several other eligibility criteria apply.
Exclusion
- None
Key Trial Info
Start Date :
August 1 1998
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2001
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00100477
Start Date
August 1 1998
End Date
June 1 2001
Last Update
September 25 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
North Florida/South Georgia Veterans Health System
Gainesville, Florida, United States, 32608